Astrotech Corporation — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended December 31, 2015 (Astrotech fiscal 2016 second quarter), not 2014 Q2 as stated in the request metadata. The figures below are unaudited; amounts are in U.S. dollars unless noted.
Business context and reporting period
Astrotech is a technology incubator and holding company. After selling its Astrotech Space Operations business in August 2014, it focused on Astro Scientific’s 1st Detect chemical analyzers, Astrogenetix biotechnology programs, and Astral Images film restoration and digitization. The quarter and six-month period ended December 31, 2015 are compared with the corresponding 2014 periods.
Key financial metrics
| Metric | Quarter ended Dec. 31, 2015 | Six months ended Dec. 31, 2015 |
|---|---|---|
| Revenue | $927,000 | $927,000 |
| Gross profit / margin | $295,000 / 32% | $295,000 / 32% |
| Operating expenses | $2.997 million | $6.547 million |
| Loss from operations | $2.702 million | $6.252 million |
| Net loss attributable to Astrotech | $2.526 million | $5.890 million |
| Loss per share attributable to Astrotech | $0.12 | $0.28 |
- Cash flow: For the six months, operating activities used $6.864 million; investing activities provided $6.796 million, primarily from investment sales and maturities; financing activities used $117,000. Cash and cash equivalents declined $185,000 to $2.145 million.
- Liquidity: At December 31, cash and short-term investments totaled $20.3 million; working capital was approximately $26.4 million. Including $5.8 million of long-term investments and the $6.1 million ASO indemnity receivable, the company reported $32.2 million in cash, investments, and receivable resources.
- Debt: No debt was outstanding at December 31, 2015.
- Balance sheet: Total assets were $37.6 million, total liabilities $2.0 million, and stockholders’ equity $35.6 million.
Material changes versus comparable periods
- Quarterly revenue rose from $4,000 to $927,000. Six-month revenue increased from $324,000 to $927,000. Current-period revenue included $685,000 from research subcontract work and $242,000 from space-grade handrail manufacturing, which management says typically occurs only every one to two years.
- Six-month gross margin increased to 32% from 13%, but operating expenses increased $899,000, principally due to a $914,000 increase in research and development spending and additional headcount at 1st Detect and Astral.
- Six-month loss from continuing operations widened to $6.061 million from $3.510 million. The prior-year period included $24.371 million of income from discontinued operations, including the ASO sale gain; consequently, prior-year net income of $20.861 million is not directly comparable with the current-period net loss.
- Available-for-sale investments had an unrealized loss reflected in accumulated other comprehensive loss, which stood at $217,000 at December 31, compared with $23,000 at June 30, 2015.
Outlook, risks, and unusual items
- Management stated that liquidity was sufficient to fund operating expenses, capital requirements, and other expected needs during the next fiscal year. The filing provides no specific revenue or earnings guidance.
- The $6.1 million ASO sale indemnity holdback was held in escrow and expected to be released in full in February 2016; the company reported no known claims against it as of the filing. Its timing and collection are relevant to liquidity.
- Customer concentration is significant: two customers together accounted for 96% of fiscal 2016 revenue to date; all fiscal 2015 revenue came from one customer. Subcontract revenue depends on deliverable acceptance, usually every three to six months.
- Other stated risks include product demand and market acceptance, government funding and procurement, competition, contract timing, technology development milestones, and the ability to raise capital. The company had a full valuation allowance against net deferred tax assets.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and procedures.
Most important facts for investors to verify
- Whether the $6.1 million ASO indemnity holdback was released and collected as expected in February 2016.
- Whether subcontract work and product sales can replace or exceed the unusual $242,000 handrail sale, and how much revenue remains dependent on a small number of customers.
- Whether operating cash use and R&D spending can be sustained by available liquidity without additional financing or materially reducing investment.
- How much of reported investment balances is readily available, and whether investment values or customer collections have changed since December 31, 2015.
- Progress on commercial adoption, government contracts, and development milestones across 1st Detect, Astral Images, and Astrogenetix.